Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas

Despite advances in the molecular characterization of mature T and NK cell lymphomas, outcomes for these patients is poor especially those with relapsed/refractory (R/R) disease. These tumors possess mutations that often result in tonic T cell receptor (TCR) signaling and an immunosuppressive tumor microenvironment. Interleukin-2-inducible T cell kinase (ITK) plays an important role in TCR signaling and T cell differentiation. Soquelitinib is a covalent oral selective ITK inhibitor that blocks Th2 differentiation while sparing Th1 cells (Th1 skewing). We conducted a phase 1 trial with soquelitinib for the treatment of R/R peripheral T cell lymphomas to determine safety, target occupancy and antitumor activity. A dose escalation design was followed by an expansion cohort to confirm dosing and identify predictive characteristics. Seventy-five patients were enrolled. No dose-limiting toxicities were observed with doses up to 600mg BID and target occupancy exceeding 80% was established for 200mg BID dose. At the 200mg BID dose, number of prior lines of therapy was found to affect antitumor activity as durable complete and partial responses were seen in 37% patients with 1-3 prior therapies; no responses were seen in patients with >3. Objective and durable tumor responses were observed in various histologic subtypes. Blood and tumor biopsies indicated that soquelitinib treatment leads to Th1 skewing, reduction of T cell exhaustion and blockade of Th2 cells. These studies demonstrate soquelitinib is active in T cell lymphomas with a mechanism related to effects on malignant T cells and/or normal T effector cells. Trial registration: NCT03952078 at www.ClinicalTrials.gov.

Authors

Institutions

Publication Details

Journal
Blood
Published
2026-08-25
DOI
https://doi.org/10.1182/blood.2026034704
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas

Tatyana A. Feldman, Nagendra Prasad Sungala, Amit Khot, Ryan A. Wilcox et al.
Blood
Lymphoma Diagnosis and Treatment
article

Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas

Tatyana A. Feldman, Nagendra Prasad Sungala, Amit Khot, Ryan A. Wilcox, Michael S. Khodadoust, Neha Mehta–Shah, John Reneau, Yuqin Song, Costas K. Yannakou, Robin Gasiorowski, Oleg E. Akilov, Dejan Radeski, Suresh Mahabhashyam, Sung‐Soo Yoon, Richard A. Miller, Youn H. Kim, Pratyush Giri, Dok Hyun Yoon, Won Seog Kim, Ho-Jin Shin, Ning Ding
article en

Abstract

Despite advances in the molecular characterization of mature T and NK cell lymphomas, outcomes for these patients is poor especially those with relapsed/refractory (R/R) disease. These tumors possess mutations that often result in tonic T cell receptor (TCR) signaling and an immunosuppressive tumor microenvironment. Interleukin-2-inducible T cell kinase (ITK) plays an important role in TCR signaling and T cell differentiation. Soquelitinib is a covalent oral selective ITK inhibitor that blocks Th2 differentiation while sparing Th1 cells (Th1 skewing). We conducted a phase 1 trial with soquelitinib for the treatment of R/R peripheral T cell lymphomas to determine safety, target occupancy and antitumor activity. A dose escalation design was followed by an expansion cohort to confirm dosing and identify predictive characteristics. Seventy-five patients were enrolled. No dose-limiting toxicities were observed with doses up to 600mg BID and target occupancy exceeding 80% was established for 200mg BID dose. At the 200mg BID dose, number of prior lines of therapy was found to affect antitumor activity as durable complete and partial responses were seen in 37% patients with 1-3 prior therapies; no responses were seen in patients with >3. Objective and durable tumor responses were observed in various histologic subtypes. Blood and tumor biopsies indicated that soquelitinib treatment leads to Th1 skewing, reduction of T cell exhaustion and blockade of Th2 cells. These studies demonstrate soquelitinib is active in T cell lymphomas with a mechanism related to effects on malignant T cells and/or normal T effector cells. Trial registration: NCT03952078 at www.ClinicalTrials.gov.

Blood
Ulsan College (KR), The University of Sydney (AU), Royal Adelaide Hospital (AU), The Royal Melbourne Hospital (AU), Cancer Prevention Institute of California (US), Hackensack University Medical Center (US), The University of Melbourne (AU), Peking University (CN), Washington University in St. Louis (US), University of Michigan (US), Epworth Hospital (AU), Concord Repatriation General Hospital (AU), Peter MacCallum Cancer Centre (AU), Liverpool Hospital (AU), Asan Medical Center (KR), Samsung Medical Center (KR), The Ohio State University Wexner Medical Center (US), University of Ulsan (KR), Peking University Cancer Hospital (CN), Portola Pharmaceuticals (United States) (US), Michigan United (US), Pusan National University Hospital (KR), University of Pittsburgh Medical Center (US), Kyung Hee University Dental Hospital (KR), Linear Clinical Research (AU), Stanford Cancer Institute, The Ohio State University (US), Sunesis (United States) (US), Sungkyunkwan University (KR)
Openalex Percentile: Top 11%
Lymphoma Diagnosis and Treatment
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.